David ebsworth galenica. Die Vorbereitungen für die Einreichung der Registrierungsunterlagen im Jahr Referat David Ebsworth - Galenica. Chief Executive Officer David Ebsworth will retire Aug. David Ebsworth is non-executive chairman at Verona Pharma Plc. com MEHR ANZEIGEN ePAPER LESEN ePAPER HERUNTERLADEN TAGS galenica gruppe pharma vifor wachstum ferinject schweiz thema ausblick medienkonferenz referat ebsworth www. David has chaired numerous private and public Aug 12, 2014 · Tulstrup and Kneubuehler, who will both report to Jornod, replace Galenica Chief Executive David Ebsworth, who will advise special projects until he retires in one year. Galenica AG, Schweiz 2014–2015: Projektbegleitung für den Vorstandsvorsitzenden von Vifor Pharma sowie von Galenica Santé bis zum Erreichen des Ruhestandsalters 2012–2014: Vorstandsvorsitzender sowie Vorsitzender des Konzernleitungsausschusses (Zürich und Bern, Schweiz) 2009-2014: Vorstandsvorsitzender von Vifor Pharma AG sowie Mitglied Sep 17, 2009 · The Board of Directors of Galenica has appointed Dr David Ebsworth as member of the Corporate Executive Committee of Galenica and CEO of Vifor Pharma. com(PDUFA-Datum: 3. August 2012) Potenzial des neuartigen Phosphatbinders PA21; Zulassungsanträge in den USA und Europa für 2012 geplant Überprüfung der OTC-Strategie für die Schweiz Lohnfertigung von BG-12 für Biogen Idec in Villars-sur-Glâne Erarbeitung einer langfristigen Strategie für die Vaxom-Produkte,<br DAVID EBSWORTH CEO Galenica Gruppe Retail 2012: Steigerung Nettoumsatz Logistics 2012: Erfolgreiche Vertei HCI 2012: Konfrontation mit vielen Vifor Pharma 2012: Agieren in einem Erfolgsfaktoren Wachstum Ferinject Innovation und Führungsstärke sin Ferinject ® - starkes Wachstum bei Anhaltende Verzögerung der Marktei Hervorragende Beruflicher Werdegang Seit 2015 selbstständiger Berater ausgewählter Unternehmen im Bereich Healthcare und Finanzinvestoren sowie Angel Investor bei ausgesuchten Firmen der Gesundheitsbranche 2009–2015 Galenica AG, Schweiz 2014–2015: Projektbegleitung für den Vorstandsvorsitzenden von Vifor Pharma sowie von Galenica Santé bis zum Erreichen des Ruhestandsalters 2012–2014 Respiratory drug developer Verona Pharma has named former Galenica CEO David Ebsworth as Non-Executive Chairman of the Board of Directors. Following a request to comment on Russian iron preparations market we have googled David Ebsworth’s speech from 13 March 2012. Nov 14, 2024 · Professor David Ebsworth to work closely alongside CEO Robin BhattacherjeeWill focus on fund raising efforts to support the planned IMPACT Phase 2b/3 trial for S-pindolol benzoate in cancer cachexiaProfessor Stefan Anker, Co-Founder of Actimed and Chair of the Scientific Advisory Board, also joins the Board of Directors London, UK – 14th November 2024. David Ebsworth zum Mitglied der Generaldirektion Galenica und CEO von Vifor Pharma ernannt. com ePAPER LESEN TAGS galenica ferinject schweiz wachstum vorjahr pharma nettoumsatz erfolgreiche vifor gruppe referat ebsworth www. Adaptable and stable fluid elimination during both short and long dwells. Galenica Santé jusqu’à l’âge de la retraite 2012–2014 : Président-directeur général et président du comité de direction du groupe (Zurich et Berne, Suisse) 2009-2014 : Président-directeur général de Vifor Pharma SA et membre du comité de direction du groupe chez Galenica SA General Information Biography Dr. David's career spans over 40 years in the global pharmaceutical industry, including Bayer AG where he became global head of the Pharmaceutical division following senior In 2012, Dr Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s Executive Committee, positions he held until 2014. com galenica. The company’s lead product, RPL554, is an inhaled PDE3/PDE4 inhibitor being developed for the treatment of asthma, COPD, and cystic fibrosis. In his earlier career, Dr Ebsworth worked with Bayer for over 19 years, heading the Canadian, North American and global pharmaceutical business. Actimed Therapeutics Ltd (“Actimed Nov 14, 2024 · Professor David Ebsworth to work closely alongside CEO Robin Bhattacherjee Will focus on fund raising efforts to support the planned IMPACT Phase 2b/3 trial for S-pindolol benzoate in cancer cachexia Professor Stefan Anker, Co-Founder of Actimed and Chair of the Scientific Advisory Board, also joins Speech David Ebsworth: Business update 2009 and - Galenica. 01. com SHOW MORE ePAPER READ DOWNLOAD ePAPER TAGS pharma vifor ferinject galenica goals venofer products countries marketing clinical www. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. David Ebsworth attended the University of Surrey. März 2012 – Medienkonferenz Seite 14/16 Thema Business Update 2011 und Ausblick 2012 waren auf vielfältige Weise bestrebt, ihre Performance zu steigern und ihre Produkte und Dienstleistungen für die Kunden attraktiver zu machen. Professor David Ebsworth, PhD has been Chairman of Actimed Therapeutics since April 2018 and has also invested in the Company. 2012 – Kontinuierliche Verbesserung der Operational Excellence in den Geschäftsbereichen Logistics und Referat David Ebsworth - Galenica. Ascot, UK – 05 April 2018. Mar 16, 2022 · Speech David Ebsworth: Business update 2009 and - Galenica. He will take up his role in mid-October 2009. com 10. 31 next year David Ebsworth, Ph. Chairman at Synlab AG, Discover David Ebsworth's known position history, network and 100 relationships. He has over 40 years of experience in the healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and Galenica Santé jusqu’à l’âge de la retraite 2012–2014 : Président-directeur général et président du comité de direction du groupe (Zurich et Berne, Suisse) 2009-2014 : Président-directeur général de Vifor Pharma SA et membre du comité de direction du groupe chez Galenica SA David Ebsworth, Ph. 2015 • Views ShareEmbedFlag David Ebsworth is the Executive Chairman of Actimed Therapeutics. Find out about his known public assets. His career spans over 35 years in the global pharmaceutical industry, during which he was Global Head of Pharmaceuticals at Bayer AG and CEO of a number of companies, including ViforPharma and Galenica. Curriculum Vitae | Prof. com Aug 12, 2014 · Tulstrup and Kneubuehler, who will both report to Jornod, replace Galenica's group chief executive David Ebsworth, who will advise on special projects until he retires at the end of August next year. He served as an Executive Vice President at Galenica. com In 2012, Dr Ebsworth was also named as Chief Executive Officer of Galenica and as Chairperson of Galenica’s Executive Committee, positions he held until 2014. In 2012, Dr Ebsworth was also named as Chief Executive Officer of Galenica and as Chairperson of Galenica’s Executive Committee, positions he held until 2014. com 2009–2015 Galenica AG, Switzerland 2014–2015: Project support for CEO of Vifor Pharma and CEO of Galenica Santé until retirement 2012–2014: CEO and Chairman of the Corporate Executive Committee (Zurich and Bern, Switzerland) 2009-2014: CEO of Vifor Pharma AG and member of the Corporate Executive Committee of Galenica AG 2003–2009 Aug 12, 2014 · Tulstrup and Kneubuehler, who will both report to Jornod, replace Galenica Chief Executive David Ebsworth, who will advise special projects until he retires in one year. 2009, Der Verwaltungsrat von Galenica hat Dr. Er wird seine Funktion Mitte Oktober 2009 antreten. He has over 40 years of experience in the healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and past global head of the Pharmaceutical Division of Bayer AG. 09. Dr David Ebsworth PhD has been Chairman of Actimed Therapeutics since April 2018 and has also invested in the Company. He has over 40 years of experience in the healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and Referat David Ebsworth - Galenica. [1] Chairman at Synlab AG, Discover David Ebsworth's known position history, network and 99 relationships. He has over 40 years of experience in the healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and Nov 25, 2014 · From October 2009 to August 2014, Dr. 6 billion, with, most notably, two FDA approvals and one EMA approval David recently retired as CEO of Galenica AG and its subsidiary Vifor Pharma Ltd, and joined SFI’s Board following its acquisition of Potter’s Herb. David has chaired numerous private and public pharmaceutical companies and also served on numerous Nov 14, 2024 · David has been Non-Executive Chairman of Actimed Therapeutics since April 2018. David has over 40 years of experience in the Pharma, Healthcare and Biotech industry. The speech bears a title “The spoken word is valid”. Aug 1, 2025 · From October 2009 to August 2014, Dr Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. com Professor David Ebsworth, Executive Chairman Professor David Ebsworth, PhD has been Chairman of Actimed Therapeutics since April 2018 and has also invested in the Company. From 2009 to 2014, Dr Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical Speech David Ebsworth: Business update 2009 and - Read more about pharma, vifor, ferinject, galenica, goals and venofer. Actimed Therapeutics appoints David Ebsworth as Executive Chairman and Stefan Anker to the Board to support S-pindolol benzoate development. 4 billion to CHF 5. (VRP. From 2009 to 2014, Dr Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. D. David has chaired numerous private and public Seite 1 und 2: DAVID EBSWORTH CEO Galenica Gruppe Seite 3 und 4: Retail 2012: Steigerung Nettoumsatz Seite 5 und 6: Logistics 2012: Erfolgreiche Vertei Seite 7 und 8: HCI 2012: Konfrontation mit vielen Seite 9 und 10: Vifor Pharma 2012: Agieren in einem Seite 11 und 12: Erfolgsfaktoren Wachstum Ferinject Nov 14, 2024 · David has been Non-Executive Chairman of Actimed Therapeutics since April 2018. He is also an advisor to a variety of CEOs at public and private organisations. ” David Ebsworth, Executive Chair of Actimed added “I look forward to working more closely with Robin to achieve our objectives. galenica. Member of the Executive Committee and CEO Vifor Pharma at Galenica AG in October 2009 to August 2014 Dr. Dr. Actimed Therapeutics Ltd (“Actimed . Nov 14, 2024 · Professor David Ebsworth to work closely alongside CEO Robin BhattacherjeeWill focus on fund raising efforts to support the planned IMPACT Phase 2b/3 trial David Raymond Ebsworth currently works at Verona Pharma Plc, as Non-Executive Chairman from 2014, SYNLAB International GmbH, as Chairman-Supervisory Board, Opterion Health AG, as Chairman from Nov 14, 2024 · David has been Non-Executive Chairman of Actimed Therapeutics since April 2018. David is a past CEO of Galenica, Vifor Pharma as well as Oxford GlycoSciences and past global head of the Pharmaceutical Division of Bayer. Among these 1 positions of which Chief Tech/Sci/R&D Officer at Interpharma Investments Ltd. Nov 14, 2024 · Professor David Ebsworth to work closely alongside CEO Robin Bhattacherjee Will focus on fund raising efforts to support the planned IMPACT Phase 2b/3 trial for S-pindolol benzoate in cancer cachexia Professor Stefan Anker, Co-Founder of Actimed and Chair of the Scientific Advisory Board, also joins the Board of Directors London, UK – 14th November 2024. At the same time, Professor Stefan Anker, Founder and Chair of Nov 14, 2024 · Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that Professor David Ebsworth will assume the role of Executive Chairman of Actimed. He also serves as Chairman of the Board & Member of Remuneration, Audit and Risk & Nomination & Corporate Governance Committee at Verona Pharma. He continues as advisor to the CEO of Vifor Pharma and Galenica Santé, the two companies which are preparing to separate out of the Galenica Group as announced in August 2014. com Speech David Ebsworth: Business update 2009 and - Galenica. David has chaired numerous private and public Nov 14, 2024 · Professor David Ebsworth to work closely alongside CEO Robin Bhattacherjee Will focus on fund raising efforts to support the planned IMPACT Phase 2b/3 trial for S-pindolol benzoate in cancer cachexia Professor Stefan Anker, Co-Founder of Actimed and Chair of the Scientific Advisory Board, also joins Referat David Ebsworth - Galenica. Ebsworth was also named as CEO of Galenica AG in 2011. Visionary new non-glucose based osmotic agent in peritoneal dialysis (PD). L), a drug development company focused on respiratory diseases, Monday announced the appointment of David Raymond Ebsworth as Non-Executive Chairman of the Board of Directors with effect from December 1. David has chaired numerous private and public pharmaceutical companies and served on many Boards as either David Ebsworth, CEO Vifor Pharma y OM Pharma. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharm Nov 24, 2014 · From October 2009 to August 2014, Dr Ebsworth served as Chief Executive Officer (CEO) of Vifor Pharma, based in Zürich, the Specialty Pharma division of Galenica AG Group, the leading pharmaceutical wholesaler and retailer in Switzerland. From October 2009 to August 2014, Dr. Der Rekrutierungsprozess machte sehr gute Fortschritte, nicht zuletzt dank der Unterstützung von Fresenius Medical Care mit ihrem ausgedehnten Netzwerk an Dialysezentren. com Referat David Ebsworth - Galenica. Nov 24, 2014 · Verona Pharma plc. Actimed Therapeutics Ltd (“Actimed 2009–2015 Galenica AG, Switzerland 2014–2015: Project support for CEO of Vifor Pharma and CEO of Galenica Santé until retirement 2012–2014: CEO and Chairman of the Corporate Executive Committee (Zurich and Bern, Switzerland) 2009-2014: CEO of Vifor Pharma AG and member of the Corporate Executive Committee of Galenica AG 2003–2009 Sep 8, 2014 · Galenica said David Ebsworth stepped down as CEO and that it is preparing its two business units -- its Vifor Pharma specialty pharma business and Galenica David Ebsworth is Non-Executive Chairman at Verona Pharma Plc. He has over 40 years of experience in the Nov 14, 2024 · Professor David Ebsworth to work closely alongside CEO Robin BhattacherjeeWill focus on fund raising efforts to support the planned IMPACT Phase 2b/3 trial for S-pindolol benzoate in cancer cachexiaProfessor Stefan Anker, Co-Founder of Actimed and Chair of the Scientific Advisory Board, also joins the Board of Directors London, UK – 14th November 2024. Aug 13, 2014 · Galenica AG (GALN), the maker of an iron-deficiency treatment and the owner of Switzerland’s biggest pharmacy network, is preparing to split into two publicly traded entities. Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of cachexia, today announces the appointment of Dr David Ebsworth as Chairman of the Board. Ebsworth succeeds Clive Page, who founded the company in 2006. David Ebsworth serves as Chairman at Opterion and Actimed Therapeutics. David Ebsworth. He has over 40 years of experience in the healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and Aug 12, 2014 · Tulstrup and Kneubuehler, who will both report to Jornod, replace Galenica Chief Executive David Ebsworth, who will advise special projects until he retires in one year. Nov 14, 2024 · David’s industry track record, contact network and Board expertise speak for themselves and will further strengthen our ability to finance and complete our planned clinical programme for this highly promising asset. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a From October 2009 to August 2014, Dr. Dr Ebsworth was also named as CEO of Galenica AG in 2011. David has chaired numerous private and public David Ebsworth, who has been CEO of Vifor Pharma since 2009 and was appointed CEO Galenica Group in 2011, has decided to step down from his operational duties and to take well-earned retirement from 31 August 2015. David Ebsworth brings an extremely wide-ranging knowledge of all aspects of the pharma business, as well as proven experience in key international pharma markets. David Ebsworth is the new CEO of Galenica Group. Member of the Supervisory Board of Sartorius AG Year of birth: 1954 Nationality: British Place of residence: Overath, Germany Member since: January 2020 Dr. The share rose the most in more than eight months. He has over 40 years of experience in the healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and David Ebsworth reports excellent results. . Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a Mar 26, 2025 · David Raymond Ebsworth currently works at Verona Pharma Plc, as Non-Executive Chairman from 2014, SYNLAB International GmbH, as Chairman-Supervisory Board, Opterion Health AG, as Chairman from Nov 14, 2024 · Professor David Ebsworth to work closely alongside CEO Robin Bhattacherjee Will focus on fund raising efforts to support the planned IMPACT Phase 2 b/3 trial for S-pindolol benzoate in cancer David Ebsworth Chairman Dr David Ebsworth, PhD, has been Chairman of Opterion Health since December 2016. During his tenure with the Galenica Group, its value increased from CHF 2. David has chaired numerous private and public pharmaceutical companies and served on many Boards as either Chairman of the audit About Actimed Therapeutics. At the same time, Professor Stefan Anker, Founder and Chair of Sep 17, 2009 · 17. Writer of action and intrigue set in times past. Reduces metabolic stress, such as glucose and insulin spikes, and weight gain. A nivel Perú la compañía comercializa los productos de las siguientes áreas terapéuticas: anemia y deficiencia de hierro, enfermedades infecciosas del tracto respiratorio y urinario y productos utilizados en problemas digestivos. David Raymond Ebsworth, Ph. David Ebsworth bringt ein sehr breites Know- how auf allen Stufen des Pharmageschäfts mit sowie eine ausgewiesene Erfahrung in wichti- gen internationalen Pharmamärkten. From 2009 to 2014, Dr Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. Sep 17, 2009 · Der Verwaltungsrat von Galenica hat Dr. Expected to prolong PD treatment window by slowing glucose-induced peritoneal fibrosis. 2009–2015 Galenica AG, Switzerland 2014–2015: Project support for CEO of Vifor Pharma and CEO of Galenica Santé until retirement 2012–2014: CEO and Chairman of the Corporate Executive Committee (Zurich and Bern, Switzerland) 2009-2014: CEO of Vifor Pharma AG and member of the Corporate Executive Committee of Galenica AG 2003–2009 Nov 14, 2024 · David has been Non-Executive Chairman of Actimed Therapeutics since April 2018. , he knows 2 people directly. Dr Ebsworth currently serves on the boards of Sartorius and Synlab. He really brings these dramatic historical events to life in his books. Nov 14, 2024 · London, UK – 14th November 2024. comDatum 13. comPA21 entwickelte sich ebenfalls ausgezeichnet, und 2011 starteten die Phase-III-Studien. Identify the source of John Dickson's network. Previously, he served as a Chairman at Wilex AG. David Raymond Ebsworth PhD 's Biography Dr Ebsworth has significant experience in leadership and management of pharma and biotech companies internationally. Improves quality of life. He previously worked at Kyowa Kirin International as a Board Member. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that Professor David Ebsworth will assume the role of Executive Chairman of Actimed. Nov 14, 2024 · David has been Non-Executive Chairman of Actimed Therapeutics since April 2018. Professor David Ebsworth, Executive Chairman Professor David Ebsworth, PhD has been Chairman of Actimed Therapeutics since April 2018 and has also invested in the Company. com Nov 14, 2024 · David has been Non-Executive Chairman of Actimed Therapeutics since April 2018. David has been Non-Executive Chairman of Actimed Therapeutics since April 2018. David has chaired numerous private and public pharmaceutical companies and also served on Dec 19, 2024 · David Ebsworth is Non-Executive Chairman at Verona Pharma Plc. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the Specialty Pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer in Switzerland. Referat David Ebsworth - Galenica. David has 40 years of experience in the Healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and past global head of the Pharmaceutical Division of Bayer AG. May 7, 2025 · David’s industry track record, contact network and Board expertise speak for themselves and will further strengthen our ability to finance and complete our planned clinical programme for this highly promising asset. com Who is David Ebsworth? David Ebsworth is non-executive chairman at Verona Pharma Plc. Speech David Ebsworth: Business update 2009 and - Galenica. He will continue to support the Galenica Group in a Special Projects role given his knowledge and excellent pharma expertise. Ebsworth has served as the Non-Executive Chairperson of our board of directors since December 2014. com London, UK – 14th November 2024. 3ewel a0kecap 7z28sp rhus7 01m glngsygt rke wzqr aw36kj pz7t

David ebsworth galenica. David has chaired numerous private and public .